CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma
Latest Information Update: 09 Dec 2022
At a glance
- Drugs Salbutamol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CONNECT1
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 07 Nov 2022 According to Teva Pharmaceuticals USA media release, data from this study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific meeting.
- 07 Sep 2022 According to Teva Pharmaceuticals USA media release, data from this trial was published in The Journal of Allergy and Clinical Immunology.
- 07 Sep 2022 Results published in Teva Pharmaceuticals Media Release.